Biogen

1D
1W
1M
3M
1Y
5Y

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Biogen and other ETFs, options, and stocks.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
8,725
Employees8,725
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
8,725
Employees8,725

BIIB Key Statistics

Market cap
39.07B
Market cap39.07B
Price-Earnings ratio
12.52
Price-Earnings ratio12.52
Dividend yield
Dividend yield
Average volume
928.13K
Average volume928.13K
High today
$267.45
High today$267.45
Low today
$262.25
Low today$262.25
Open price
$262.25
Open price$262.25
Volume
703.60K
Volume703.60K
52 Week high
$311.88
52 Week high$311.88
52 Week low
$187.16
52 Week low$187.16

BIIB News

Investor's Business Daily 8h
Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

Ionis stock jumped Thursday after a Food and Drug Administration panel offered a mixed view of its Biogen (BIIB)-partnered treatment for a deadly neurodegenerat...

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement
Benzinga 8h
iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation ... - Benzinga

Tempe, AZ --News Direct-- By Rachael Green, Benzinga Interested in investing in iMetabolic BioPharma? Click here to get started! iMetabolic BioPharma (iMBP)...

iMetabolic BioPharma's Alzheimer's Disease Therapeutic Innovation ... - Benzinga
Benzinga 8h
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted 9 yes - 0 no, indicating sufficient evidence showing a reduction in plasma neurof...

FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder

Analyst ratings

63%

of 32 ratings
Buy
62.5%
Hold
37.5%
Sell
0%

BIIB Earnings

$0.00
$1.89
$3.79
$5.68
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Q2 FY22
Q3 FY22
Q4 FY22
Q1 FY23
Estimated
per share
Estimated per share
Actual
Expected May 3, Pre-Market
ActualExpected May 3, Pre-Market

More BIIB News

Yahoo Finance 21h
Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS - Yahoo Finance

Biogen Inc. SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United States CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEW...

Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS - Yahoo Finance
MarketWatch 23h
Biogen ALS drug considered not effective by FDA advisory panel - MarketWatch

Biogen Inc. BIIB, -1.85% received a setback late Wednesday after a Food and Drug Administration advisory committee said the biotech drug maker’s proposed amyotr...

Biogen ALS drug considered not effective by FDA advisory panel - MarketWatch
Yahoo Finance 2d
Biogen Inc. Stock Sinks As Market Gains: What You Should Know - Yahoo Finance

Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session. This change lagged the S&P 500's 1.3% gain on...

Biogen Inc. Stock Sinks As Market Gains: What You Should Know - Yahoo Finance
MarketWatch 2d
Wall Street predicts approval for another ALS drug - MarketWatch

It appears likely that a new drug to treat amyotrophic lateral sclerosis (ALS) will get approval in the U.S. Regulators shared their thinking ahead of an adviso...

Wall Street predicts approval for another ALS drug - MarketWatch
Benzinga 2d
Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit

FDA's Peripheral and Central Nervous System Drugs Advisory Committee will virtually meet on Wednesday, March 22, to discuss Biogen Inc's (NASDAQ: BIIB) ALS drug...

Despite Failed Phase 3 Study, FDA Staff Says Biogen's ALS Drug May Have Clinical Benefit
Reuters 3d
FDA staff says safety issues with Biogen's ALS drug to not prevent ... - Reuters

March 20 (Reuters) - The U.S. health regulator's staff said on Monday safety issues with Biogen Inc's (BIIB.O) drug to treat an ultra-rare form of...

FDA staff says safety issues with Biogen's ALS drug to not prevent ... - Reuters
MarketWatch 6d
Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations - MarketWatch

By Josh Beckerman Sangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration a...

Sangamo Shares Down 8% After Hours as Novartis, Biogen End Collaborations - MarketWatch
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.